Shots:
- Under Dzuveo agreement, AcelRx to receive ~$55M as an up front and commercial milestones in addition to 35% to 45% revenue share on net sales of Dzuveo. AcelRx will manufacture and supply Dzuveo while Aguettant gets the right to commercialize Dzuveo in the EU
- As per second agreement, Aguettant has the right to receive ~$24M as commercial milestone at ~$60M annual sales levels in addition to 40 to 45% revenue share on net sales of the two pre-filled syringe products, following their approval in the US
- AcelRx obtains the rights to file NDAs and commercialize two pre-filled syringe product in the US
Click here to read the full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US first appeared on PharmaShots.
